| D |
|
D1596-R1668 of von Willebrand factor is a minimal region recognized as a specific substrate for ADAMTS-13
|
| Kokame K., Matsumoto M., Fujimura Y., Miyata T. |
| |
|
Dark chocolate inhibits platelet aggregation in healthy volunteers
|
| Kennedy G., Innes A. J., Mclaren M., Belch J. J. F. |
| |
|
Day-care or short-stay surgery and venous thromboemolism: an overview
|
| Hoppener M. R., Ettema H. B., Kraaijenhagen R. A., Verheyen C. C. P. M., Büller H. R., Henny CH. P. |
| |
|
DDAVP normalized the bleeding time in patients with congenital platelet thromboxane A2 receptor abnormality
|
| Fuse I. |
| |
|
D-dimer and residual vein thrombosis assessed at 3 months after anti-coagulation withdrawal are independent risk factors for recurrent venous thromboembolism
|
| Cosmi B., Legnani C., Cini M., Valdre L., Guazzaloca G., Coccheri S., Palareti G. |
| |
|
d-dimer as a prognostic marker in patients with pulmonary embolism
|
| Söhne M., Ten Wolde M., Douketris J. D., Büller H. R. |
| |
|
D-dimer for the exclusion of acute deep venous thrombosis and pulmonary embolism: a systematic review
|
| Stein P. D., Hull R. D., Patel K. C., Olson R. E., Ghali W. A., Brant R., Biel R. K., Bharadia V., Kalra N. K. |
| |
|
d-dimer levels: a prognostic value in patients with chronic atrial fibrillation
|
| Mahé I., Drouet L., Simoneau G., Minh-Muzeaux S., Caulin C., Bergmann J. F. |
| |
|
Debate: management of thromboembolism
|
| |
| |
|
Decrease of thrombophilia variables by aggressive vs. conventional atorvastatin treatment in patients with type 2 diabetes mellitus
|
| Van De Ree M. A., De Maat M. P. M., Kluft C., Meinders A. E., Princen H. M. G., Huisman M. V. |
| |
|
Decreased expression of protein C inhibitor in renal cell carcinoma cells is partly caused by DNA methylation
|
| Hayashi T., Nishioka J., Kamada H., Asanuma K., Akita N., Ido M., Gabazza E. C., Suzuki K. |
| |
|
Deep venous thrombosis of the arm: comparison of sulodexide and acenocoumarol for the secondary prevention of venous thromboembolism
|
| Lasierra J., Polo A. B., Ruiz M. L. |
| |
|
Defective vWF–Fibrin–GPIb interaction causes impaired prothrombin consumption in Bernard–Soulier Syndrome
|
| Al Dieri R., Bellucci S., Béguin S., Hemker H. C., Caen J. |
| |
|
Deficiency in one Gas6 receptor (Axl, Sky or Mer) protects mice against thrombosis because of a platelet dysfunction
|
| Angelillo-Scherrer A., Charvier S., Plaisance S., Flores N., Savi P., Schaeffer P., Herbert J. M., Lemke G., Goff S., Matsushima G., Earp S., Collen D., Carmeliet P. |
| |
|
Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice
|
| Lijnen H., Demeulemeester D., Collen D., Maquoi E. |
| |
|
Definitions of the post–thrombotic syndrome: a comparison with invasive venous pressure measurement
|
| Kolbach D. N., Prins M. H. |
| |
|
Degradation pathway of the naturally occurring mutants of protein C and plasmin inhibitor by the proteasome
|
| Nakahara M., Koyama T., Shibamiya A., Nakazawa F., Hirosawa S. |
| |
|
Deletion of residue Ala2201 in the factor VIII C2 domain impairs FVIII interactions with phospholipids and vWF and results in mild hemophilia A
|
| Jacquemin M., D'Oiron R., LAVEND'Homme R., Benhida A., Bordet J., Négrier C., Peerlinck K., Vermylen J., Lavergne J. M., Saint-Remy J. M. |
| |
|
Delivering the promise of oral direct thrombin inhibitor therapy to medical practice
|
| Halperin J. |
| |
|
Demonstration of a tissue factor pathway inhibitor-2 (TFPI-2) mRNA synthesis by pure villous cytotrophoblast cells isolated from term human placentas
|
| Hubé F., Reverdiau P., Iochmann S., Trassard S., Thibault G., Gruel Y. |
| |
|
Demonstration of activation of integrin aIIbb3 by inside-out signaling in a megakaryocytic cell line, CMK
|
| Kashiwagi H., Tomiyama Y., Shiraga M., Honda S., Kosugi S., Kiyoi T., Kato H., Kurata Y., Matsuzawa Y. |
| |
|
Dental implants in anti-coagulated out-patients
|
| Martinelli F., Bacci C., Cordioli G. P., Girolami A. |
| |
|
Desaggregation of ristocetin-induced platelet aggregates by an inhibiting anti-GPIb MoAb
|
| Vanhoorelbeke K., Pareyn I., Deckmyn H. |
| |
|
Designing an advanced category rFVIII concentrate
|
| Ewenstein B. |
| |
|
Desmopressin subcutaneous administration enhances platelet response ‘in vivo’ to Platelet-Activating Factor (PAF) and causes a rise in interleukin-6 plasma levels in haemophilia A and von Willebrand disease type I
|
| Musso R., Cultrera D. C., Sortino G., Del Fabro V., Ferlito C., Azzaro M. P., Di Francesco E., Giustolisi R. |
| |
|
Detection of Ala601-Thr mutation in dysplasminogenemic patients with thrombosis in Korean population
|
| Song K., Lee S. M., Choi J. R., Kim G. H., Song J. W. |
| |
|
Detection of antiphospholipid antibodies
|
| Arnout J. |
| |
|
Detection of conformational transformation of antithrombin in blood by crossed immunoelectrophoresis: new application for a classical method. Effect of temperature in plasmatic antithrombin; role in senescence of antithrombin and thrombosis
|
| Corral J., Rivera J., Martínez C., González-Conejero R., Miñano A., López M. F., Vicente V. |
| |
|
Detection of lupus anticoagulant: development of a new precise, sensitive and specific aPTT-based assay
|
| Humpich M., Schmitt J., Seifried E., Bauersachs R., Lindhoff-Last E. |
| |
|
Detection of procoagulants with a more reliable nonactivated clotting test
|
| Exner T., Joseph J., Low J., Connor D., Ma D. |
| |
|
Detection of the factor XIIIA Val34Leu polymorphism in Thais
|
| Komanasin N., Chammanthoon S., Suttiprapa S., Mongkolwongroj P., Fucharoen G., Silaruks S., Kiatchoosakun S., Tassanawiwat P. |
| |
|
Detection of Thrombomodulin (TM) Ala455Val polymorphism using sequence-specific primer–polymerase chain reaction (PCR) in patients with severe obstetric complications
|
| Ayman I., Ibrahim A. H., Perez-Casal M., Alfirevic Z., Toh C. H. |
| |
|
Detection the 3614 G > A (R1205H) mutation in the VWF gene in 26 Spanish patients with high penetrance dominant type 1 von Willebrand disease
|
| Casaña P., Haya S., Espinós C., Cid A. R., Aznar J. A. |
| |
|
Determinants of delayed thrombus regression after deep vein thrombosis of the lower limbs: a prospective cohort study
|
| Ageno W., Dentali F., Manfredi E., Mera V., Squizzato A., Marchesi C., Steidl L., Venco A. |
| |
|
Determination of direct thrombin inhibitors like hirudin in plasma – Comparison of the Ecarin Chromogenic Assay (ECA) with the Ecarin Clotting Time (ECT) and the Activated Partial Thromboplastin Time (APTT)
|
| Lange U., Olschewski A., Heider A., Nowak G., Bucha E. |
| |
|
Determination of effective concentrations of recombinant factor VIIa (rFVIIa) for Glanzmann thrombasthenia patients by using thrombin generation in platelet-rich plasma (PRP) and platelet-poor plasma (PPP)
|
| Bordet J. C., Trzeciak M. C., Negrier C. |
| |
|
Determination of free sulfhydryls in human factor VIII
|
| Kumar H., Healey J. F., Lollar P., Durrani M. J. |
| |
|
Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia
|
| Gerdsen F., Wenning B., Bauersachs R., Lindhoff-Last E. |
| |
|
Determination of High-Molecular-Weight von Willebrand factor multimers and their impact on specific VWF-activities in VWF/FVIII-concentrates
|
| Walter O., Budde U., Muysers C., Metzner H. J., Suiter T. M. |
| |
|
Determination of overall hemostasis potential in different coagulation factors deficient plasma and in plasma samples from patients with hemophilia A and B
|
| Antovic A., Petrini P., Blombäck M., He S. |
| |
|
Determination of the different forms of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with hemophilia A, hemophilia B and von Willebrand disease
|
| Antovic J., Schulman S., An S. S. A., Greenfield R., Blombäck M. |
| |
|
Determination of the interassay variability of d-Dimer measurements near the critical cut-off point used for the exclusion of venous thromboembolism, on the MDA-180 coagulation analyzer
|
| Hammouda W., Schiavone A., Gotanco G. |
| |
|
Determinations of plasma protein C activity and antigen levels in patients with liver diseases and its clinical significance
|
| He X. F., Wen Z. B., Xiong S. L., Han J. Z., Li J. C., He S. L. |
| |
|
Developing hematopoietic stem cells as targets for gene therapy of hemophilia A
|
| Tonn T., Herder C., Becker S., Grez M., Seifried E. |
| |
|
Development of a biosensor system for self-testing the intensity of anti-coagulation by anti-coagulated patients in capillary whole blood
|
| Thuerlemann C., Frenkel E. J., Dinger R., Haeberli A. |
| |
|
Development of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM)
|
| Mitterer A., Mundt W., Bjornson E., Dorner F. |
| |
|
Development of anticoagulant drugs - using orthopedic surgery as a proof of principle
|
| Dahl O. |
| |
|
Development of bifunctional inhibitors of both platelet aggregation and factor Xa
|
| Lu X., Lu D., Lu X., Shang D., Morgan H., Davies J., Egglezou S., Goodwin C., Greenidge P., Scully M., Kakkar V. |
| |
|
Development of economic and outcomes model of hemophilia treatment in Latin America and South-east Asia
|
| Roberts H., Evans C., Sagrolikar A., Poulios N., Gomperts E. |
| |
|
Development of hemostasis in the very low birth weight premature infants
|
| Salonvaara M., Riikonen P., Kekomäki R., Heinonen K. |
| |
|
Development of inhibitors against factor VII in patient with severe factor VII deficiency
|
| Ingerslev J., Sørensen B., Christiansen K., Larsen H., Philips M., Herrmann F., Bernardi F., Schved J. F., Auerswald G., Mariani G. |
| |
|
Development of novel delivery systems of aprotinin
|
| Larionova N., Moroz N. A., Balabushevich N. G., Villemson A. L. |
| |
|
Development of small molecule compounds that inhibit PAI-1 activity in vitro and in vivo
|
| Wu Q., Tran K., Liang A., Wu F., Ye B., Wang Y-X., Vergona R., Morser J., Eitzman D., Zhao Z. |
| |
|
Development of the Canadian hemophilia outcomes – Kids Life Assessment Tool (CHO-KLAT)
|
| Young N. L., Bradley C. S., Wakefield C. D., Lau C., Barnard D., Blanchette V. S., Mccusker P. J. |
| |
|
Development, scale up and characterization of the first regional high purity Factor VIII: the Argentinean experience
|
| Oviedo S., Zingale G., Moya C., Bernadi M. E., Vitali M. S., Zarzur J. |
| |
|
Diagnosing pulmonary embolism with clinical assessment, d-dimer, venous ultrasound and helical computed tomography: a multicenter management study
|
| Perrier A., Roy P. M., Aujesky D., Chagnon I., Howarth N., Gourdier A. L., Leftheriotis G., Bargouth G., Cornuz J., Hayoz D., Bounameaux H. |
| |
|
Diagnosis of deep vein thrombosis in hospitalized elderly patients: poor discriminant value of clinical pretest probability unless integrated by d-dimer assay
|
| Pini M., Marchini L., Giordano A., Denti L., Mandrioli R., Valenti G. |
| |
|
Diagnosis of factor XIII deficiency – room for improvement? Experience with the UK NEQAS (Blood Coagulation) proficiency testing programme
|
| Jennings I., Kitchen S., Kitchen D., Woods T. A. L., Preston F. E. |
| |
|
Diagnosis of neonatal alloimmune thrombocytopenic purpura (NAITP) by genotyping and human platelet antigen frequency in the Indian population
|
| Mohanty D., Kulkarni B., Ghosh K., Shetty S., Pawar A., Udani R. H. |
| |
|
Diagnostic performances of two new d-dimer assays in the diagnostic work-up of patients with suspected pulmonary emboli
|
| Kruip M. J. H. A., Van Der Heul C., Buller H. R. |
| |
|
Diagnostic utility of Simplify d-dimer – a new d-dimer test for patients with suspected venous thromboembolism
|
| Low J., Joseph J., Shorey N., Mcgrath M., Javen D. |
| |
|
Diesel exhaust particles deposited in the lung enhance thrombus formation in peripheral vessels in an in vivo model of vascular thrombosis
|
| Nemmar A., Nemery B., Hoet P. H. M., Vermylen J., Hoylaerts M. F. |
| |
|
Diet-induced hyperhomocysteinemia leads to a dysfibrinogenemia, elevated levels of plasminogen activator inhibitor-1 (PAI-1) and delayed clot lysis
|
| Hoffman M., Sauls D. L., Kinlaw L. M. |
| |
|
Difference in binding of human and murine glycoprotein VI to collagen-related peptide and fibrillar collagen
|
| O'Connor M. N., Smethurst P. A., Jennings N. S., Farndale R. W., Ouwehand W. H. |
| |
|
Differences between predictive factors for PE and DVT recurrences: results from 5 randomized trials
|
| Mismetti P., Quenet S., Laporte S., Epinat M., Décousus H. |
| |
|
Differences in perioperative coagulation between Japanese and other ethnic groups undergoing laparoscopic cholecystectomy
|
| Iwade M., Iwade K., Tsunoda C., Nomura M., Ozaki M. |
| |
|
Differences in protease activated receptor-1 stimulation between vWF and P-selectin release in endothelial cells-implications of distinct signaling of Weibel–Palade release
|
| Cleator J. H., Mazzoni M. R., Vaughan D. E., Hamm H. E. |
| |
|
Differences in Th1- and Th2-like cytokine patterns between patients with antiphospholipid syndrome and with lepromatous leprosy-related aPL
|
| Martinuzzo M., De Larrañaga G., Bocassi A., Forastiero R. |
| |
|
Different blood flow parameters between high-shear conditions in patients with type 1 and type 2 diabetes mellitus
|
| Laszló P. |
| |
|
Different classes of contrast media affect the formation and subsequent lysis of thrombi formed in vitro in whole blood under conditions of flow
|
| Jones C. I., Goodall A. H. |
| |
|
Different distribution of antithrombin and thrombomodulin in endotoxin-treated rat: effect of antithrombin and activated protein c concentrates and nafamostat mesilate
|
| Eguchi Y., Terada Y., Hasegawa H., Tani T., Nosaka S. |
| |
|
Different pattern of hemostatic abnormalities in infectious and noninfectious systemic inflammatory response syndrome (SIRS)
|
| Malyszko J., Czaban S., Krajewski J., Wolczynski S., Malyszko J., Siemiatkowski A., Mysliwiec M. |
| |
|
Different risk of pulmonary embolism development in patients with deep-vein thrombosis from North-Western Russia having either factor V Leiden or prothrombin G20210A mutation
|
| Kapustin S. I., Filanovskaya L. I., Mitchell M. J., Blinov M. N., Savidge G. F. |
| |
|
Different thromboprophylaxis approaches in patients undergoing knee arthroscopy (KANT study): interim report of prospective randomized study
|
| Camporese G., N'Tita K., Rossi F., Bernardi E., Verlato F., Salmistraro G., Cordova R., Franz F., Hartmann L., Simioni P., Prandoni P., Andreozzi G. M. |
| |
|
Differential diagnostics of abnormal uterine bleeding
|
| Makatsaria A. D., Saidova R. A. |
| |
|
Differential effects of tissue factor haploinsufficiency during LPS stimulation
|
| Schoenmakers S. H. H. F., Groot A. P., Reitsma P. H., Spek C. A. |
| |
|
Differential effects of unfractionated heparin and a low molecular weight heparin on anti-thrombin activity during the treatment of deep vein thrombosis
|
| Hoppensteadt D., Mayuga M., Lietz H., Florian-Kujawski M., Ahmad S., Frapaise X., Bacher P., Breddin H. K., Reid U., Fareed J. |
| |
|
Differential geographic distribution of Factor V Leiden and Factor II Leiden in a French native population (the Fitenat study)
|
| Mazoyer E., Gueguen R., Tiret L., Paulin D., Ripoll L., Bal dit Sollier C., Drouet L. |
| |
|
Differential role of phosphatidylinositol 3-kinase in glycoprotein Ib-mediated platelet activation
|
| Asazuma N., Wu Y., Satoh K., Yatomi Y., Berndt M. C., Ozaki Y. |
| |
|
Differential use of variable domains of D3H44 antibody in binding to tissue factor or to an anti-idiotypic antibody
|
| Lipari M., Krishnamurthy R., Eigenbrot C., Meng Y. G., Wong T., Moran P., Bullens S., Kirchhofer D. |
| |
|
Differentiation of factor VIII-specific memory B cells into anti-factor VIII antibody-secreting cells requires direct interaction between memory B cells and activated T cells but is not dependent on factor VIII-specific T cells
|
| Hausl C., Ahmad R. U., Schwarz H. P., Turecek P. L., Dorner F., Reipert B. M. |
| |
|
Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues
|
| Tjernberg A. P., Vos H. L., Bertina R. M., Castaman G., Eikenboom J. C. J. |
| |
|
Dimerization of beta2-glycoprotein I is necessary for binding to and activation of endothelial cells
|
| De Laat H. B., Lutters B. C. H., Derksen R. H. W. M., De Groot P. G. |
| |
|
Dimers of b2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2: an explanation for arterial thrombosis in the anti-phospholipid syndrome
|
| Lutters B. C. H., Derksen R. H. W. M., Tekelenburg W. L., Lenting P. J., Arnout J., De Groot P. G. |
| |
|
Direct association of HCII and red blood cells
|
| Chitolie A., Mackie I. J., Machin S. J. |
| |
|
Direct detection of factor IX gene deletions in Indian hemphiliacs by multiplex PCR
|
| Shetty S., Ghosh K., Mohanty D. |
| |
|
Discontinuation of long-term oral anticoagulation (OAC): effects of concomitant administration of low-molecular weight heparin (LMWH) during the termination period – a prospective study
|
| Sarif J., Lindhoff-Last E., Bauersachs R. |
| |
|
Discrepancies in potency assessment of B-domain deleted recombinant factor VIII among different one-stage factor VIII clotting assays
|
| Steiner B., Von Pape K.-W., Burstein C., Bohner J. |
| |
|
Disease genetics and recent advances in pharmacogenetics
|
| Mooser V., Waterworth D. M., Isenhour T., Middleton L. |
| |
|
Disseminated intravascular coagulation after varicella infection
|
| Lischetzki G., Topf H. G., Benz K., Harms D., Rascher W., Klinge J. |
| |
|
Disseminated intravascular coagulation in surgary
|
| Kuznik B., Vitkovsky YU., Likhanov I., Sizonenko V., Abdulayev KH. |
| |
|
Dissociation of the JAM-1/avb3 complex followed by signaling through JAM-1 is key to the angiogenic response induced by bFGF: an explanation of the avb3 paradox
|
| Naik M. U., Kelley P. B., Mousa S. A., Skarnes W., Parkos C. A., Naik U. P. |
| |
|
Dissolving effects of anti-GP IIb/IIIa agents on platelet thrombi formed on the collagen surface under blood flow conditions
|
| Goto S., Tamura N., Ishida H., Handa S. |
| |
|
Distinct dose-dependent effects of plasmin and TPA on coagulation and haemorrhage
|
| Stewart D., Kong M., Novokhatny V., Jesmok G., Marder V. |
| |
|
Diverse roles of LRP in clearance of proteases and in signaling
|
| Strickland D., Ranganathan S. |
| |
|
DNAzymes targeting immediate-early genes: potential therapeutic tools in in-stent restenosis and angiogenesis
|
| Khachigian L. |
| |
|
Does cyclooxygenase-2 have a role in aspirin-dependent platelet function?
|
| Murugesan G., Gurm H. S., Gerber C. E., Kottke-Marchant K. |
| |
|
Does DVT exist in Asia? – The AIDA study (assessment of the incidence of Deep Vein Thrombosis in Asia following major orthopedic surgery): study rationale and interim results
|
| Piovella F., Turpie A. G., Planes A., Wang C. J., Gallus A., Lee W. C., Lee K. K. C., Housan L. V., Perdriset G., Rouillon A. |
| |
|
Does LMWH improve long-term survival in patients with cancer?
|
| Kakkar A. |
| |
|
Does plasma homocysteine influence the in vitro anti-coagulant response to activated Protein C?
|
| Podda G., Zighetti M. L., Lecchi A., Lombardi R., Faioni E. M., Cattaneo M. |
| |
|
Does rebound exist? A comparison of venous thromboembolic event rates in the post-treatment period for patients randomized to long-term low-molecular-weight heparin vs. warfarin sodium
|
| Pineo G. F., Hull R. D., Mah A. F., Lite Investigators† |
| |
|
Does thromboelastography demonstrate hypercoagulability in patients with both a clinical history of thrombosis and the lupus anti-coagulant antibody?
|
| Hadfield A. L., Pierce J. M. T., Royle D. E., Bruty S. J., Lavender F. L., O'Shaughnessy D. F. |
| |
|
Domain 5 (D5) of high molecular weight kininogen (HK) induces aggregation of human platelets
|
| Bradford H. N., Colman R. W., Isordia-Salas I. |
| |
|
Dominant negative anticoagulant effects of mouse recombinant meizothrombin precursor R157A/R268A delay thrombus formation in a mouse injured carotid artery
|
| Shim K., Zhu H., Westfield L. A., Sadler J. E. |
| |
|
Dose-dependent inhibition of thrombosis by melagatran in a nonhuman primate model
|
| Kotzé H., Gruber A., Marzec U., Sarich T., Carlsson S., Hanson S. |
| |
|
Dosing with rFVlla - based on current evidence
|
| Hedner U. |
| |
|
Downregulation of Factor IXa in the Factor Xase complex by protein Z-dependent protease inhibitor (ZPI)
|
| Yegneswaran S., Ruan L., Heeb M. J. |
| |
|
Down-regulation of PAI-1 expression by natriuretic peptides is mediated by MAPK cascade in human endothelial cells
|
| Pawlowska Z., Jerczynska H., Baranska P., Swiatkowska M., Cierniewski C. S. |
| |
|
Dramatic improvement in the care and management of patients with DVT in a large UK hospital
|
| Nokes T., Lester Z., Cornelius A., Fulton J. |
| |
|
Drotrecogin alfa (activated) inhibits degradation of cytokine-mRNA in an endothelial model of inflammation
|
| Brueckmann M., Lang S., Weiler H. M., Liebe V., Hoffmann U., Borggrefe M., Haase K. K., Huhle G. |
| |
|
Drug-dependent antibodies are accompanied by drug-specific antibodies in Quinine-induced immune mediated thrombocytopenia
|
| Bougie D., Wilker P. R., Aster R. H. |
| |
|
Drug-dependent antibodies, what binds where?
|
| Bougie D., Wilker P. W., Birenbaum J. A., Aster R. H. |
| |
|
Drugs sources and clinical benefits: Arixtra a new model
|
| Buller H. |
| |
|
DRVVT testing for lupus identification: a comparison of two methods
|
| Lanning L., Aghighi S., Brooks S., Perry D. |
| |
|
Duplex screening for quality assurance of postoperative thromboembolism prophylaxis in neurosurgery – Krefeld Study ‘Thrombo 2000’
|
| Van Den Berg E., Bahr W., Hess J., Van Eck A. T. C. J., Schmutzler-Baas A., Hamacher J., Ulrich F. |
| |
|
Duration of prophylaxis for venous thromboembolism after total hip and knee arthroplasty: findings from the global orthopedic registry (GLORY)
|
| Friedman R., Gallus A., Cushner F., Kuznetsova P., Anderson F. |
| |
|
DX-9065a, a direct factor Xa inhibitor prevents both arterial and venous thrombosis in rats via blocking prothrombinase complex activity – comparison with fondaparinux, an antithrombin dependent factor Xa inhibitor
|
| Fukuda T., Honda Y., Matsumoto C., Ishihara H., Sugiyama N. |
| |
|
Dynamics of changes of parameters of a hemostasis in patients with sepsis
|
| Berkovskiy A. L., Rudakov V. E., Sergeeva E. V., Vasilyev S. A., Gavrilova E. B., Avdonin P. V., Galstyan G. M., Gorodestskiy V. M. |
| |
|
Dynamics of changes of parameters of a hemostasis in patients with sepsis
|
| Rudakova V. E., Sergeeva E. V., Vasiljev S. A., Berkovsky A. L., Orel E. B., Gavrilova A. V., Avdonin P. V., Galtsjan G. M., Gorodetsky V. M. |
| |
|
Dynamics of the extracellular matrix degradation with the participation of urokinase-plasmin system: a mathematical model
|
| Khanin M., Ignatiev D. yU. |
| |
